CG MedTech Calls Extraordinary General Meeting for 5-to-1 Stock Consolidation and Charter Amendment
CG MedTech resolved on June 30, 2026 to convene an extraordinary general meeting on August 11, 2026.
The main agenda includes a proposal for a 5-to-1 reverse stock split, increasing the par value from 500 won to 2,500 won, and a corresponding amendment to the articles of incorporation. The total number of outstanding shares will decrease to approximately one-fifth of the current count.
The consolidation aims to boost the share price and meet listing maintenance requirements, but it will reduce stock liquidity and may lower accessibility for retail investors in the short term. The proposals remain subject to shareholder approval.
No share buyback or dividend plans were disclosed in this filing.
[AI Summary]CG MedTech's proposed reverse stock split is a structural measure to manage share price and listing compliance without fundamental business improvement. The impact on shareholder value is neutral in the near term, and the final outcome depends on shareholder vote and subsequent corporate performance.
KOSDAQ Filing Information
Resolution to Convene a General Meeting of Shareholders (Extraordinary General Meeting)